Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.
GlobalData on MSN15h
Abbott’s Amplatzer Amulet shows promise in atrial fibrillation trialAbbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...
Medpage Today on MSN20h
More Lp(a)-Reducing Tx; Cardiac Denervation for Afib; LAA Occluders at 5 Years(JAMA Cardiology) Five-year results from the Amulet IDE trial suggested similar performance of the Amulet and Watchman 2.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback